Ko, Kwang-Pil; Ma, Seung Hyun; Yang, Jae-Jeong; Hwang, Yunji; Ahn, Choonghyun; Cho, Young-Min; Noh, Dong-Young; Park, Byung-Joo; Han, Wonshik; Park, Sue K
Breast cancer research and treatment
2015Sep ; 153 ( 2 ) :361-70.
PMID : 26293146
ÀúÀÚ »ó¼¼Á¤º¸
Ko, Kwang-Pil -
Ma, Seung Hyun -
Yang, Jae-Jeong -
Hwang, Yunji -
Ahn, Choonghyun -
Cho, Young-Min -
Noh, Dong-Young -
Park, Byung-Joo -
Han, Wonshik -
Park, Sue K -
ABSTRACT
Previous observational studies have suggested that metformin in diabetes patients may reduce breast cancer risk more than the reductions from other anti-diabetes medications. This randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy of metformin for controlling physical and metabolic profiles related to prognosis and adverse events in non-diabetic breast cancer patients. Female breast cancer patients (N = 105), at least 6 months post-mastectomy, with obesity (??5 kg/m(2)) and/or pre-diabetes (fasting blood sugar levels ??00 mg/dL), were randomly assigned to three groups (placebo, metformin 500 mg, and metformin 1000 mg) stratified by tamoxifen use. A linear mixed model for repeated measurements among three groups and ANOVA for profile differences during 6 months of treatment were used for the intention-to-treat analysis. The metformin 1000 mg group had a significantly greater decline in glucose and HbA1c levels between treatment weeks 0 and 6 month (p = 0.008 and 0.009, respectively), and the declines increased with an increase in body mass index (BMI) level (p interaction with BMI = 0.007 and 0.067, respectively). A marginally significant different effect from the metformin 1000 mg treatment was detected for glucose and HbA1c levels (p interaction = 0.084 and 0.063, respectively) in the intention-to-treat analysis. Metformin 1000 mg treatment had a favorable effect on controlling glucose and HbA1C levels in obese non-diabetic breast cancer patients, indicating prognostic importance. Further trials are needed to elucidate the risk-benefit ratio of long-term use of metformin.
Metformin Breast cancer Glucose Postoperative adjuvant
MESH
Biomarkers, Breast Neoplasms/*complications/*drug therapy/metabolism/pathology, Female, Humans, Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use, Metformin/administration & dosage/adverse effects/*therapeutic use, Neoplasm Staging, Obesity/*complications, Time Factors, Treatment Outcome
¸µÅ©